JPMorgan Confident Orexigen's (OREX) Will Receive FDA Approval; Comments on Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Express Scripts (ESRX) Deal is Huge Win for VIVUS (VVUS); Qsymia Reimbursement Will Improve
December 24, 2012 10:36 AM ESTVIVUS, Inx. (Nasdaq: VVUS) is heading in the right direction on the holiday-shortened trading session Monday following bullish comments over Qsymia reimbursement.
According to JPMorgan analyst Cory Kasimov and his team note the disclosure last week that Express Scripts (Nasdaq: ESRX) would be adding Qsymia to its national pharmacy... More
Orexigen Therapeutics (OREX) to Webcast JPMorgan Healthcare Presentation
December 24, 2012 8:31 AM ESTOrexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the JP Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Tuesday, January 8, 2013 at 10:30 a.m. Pacific Time. To listen to the live webcast or a replay... More
Arena (ARNA), Orexigen (OREX) on Watch as Major PBM Adds Qsymia to Formularies List (VVUS)
December 20, 2012 6:34 AM ESTVIVUS, Inc. (NASDAQ: VVUS) peers Arena Pharmaceutials (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) are ticking higher following reports that major Pharmacy Benefit Manager (PBM) Express Scripts (Nasdaq:... More
Orexigen (OREX) Slumps as Many Expected 'Better News' for Contrave
December 18, 2012 3:23 PM ESTOrexigen Therapeutics, Inc. (Nasdaq: OREX) shares are lower on the session following... More
Orexigen (OREX) Updates on Contrave; to Resubmit NDA, Sees FDA Approval in Q413
December 18, 2012 8:32 AM ESTOrexigen Therapeutics, Inc. (Nasdaq: OREX) provided a clinical trial update of the Light Study as well as results of recent market research at its Analyst Day meeting in New York City. Orexigen reported that the screening of new patients for the Light Study, the cardiovascular outcomes trial evaluating Contrave® (Naltrexone SR/Bupropion SR), is now complete. Approximately 9,000 patients will be randomized in the study within the next few weeks. An interim analysis of the Light Study will occur after approximately 87 major adverse cardiovascular events (MACE) are accrued in the study. Although it... More
